Literature DB >> 5322500

Role of oral glycerol in glaucoma.

P Awasthi, S N Srivastava.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5322500      PMCID： PMC506178          DOI： 10.1136/bjo.49.12.660

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  7 in total

1.  EFFECT OF ORAL GLYCEROL OF INTRAOCULAR PRESSURE IN NORMAL AND GLAUCOMATOUS EYES.

Authors:  S M DRANCE
Journal:  Arch Ophthalmol       Date:  1964-10

2.  ORAL GLYCEROL IN GLAUCOMA.

Authors:  T A CASEY; P D TREVOR-ROPER
Journal:  Br Med J       Date:  1963-10-05

3.  GLYCERIN. AN ORALLY EFFECTIVE OSMOTIC AGENT.

Authors:  R P THOMAS
Journal:  Arch Ophthalmol       Date:  1963-11

4.  Urea in the management of head injuries.

Authors:  E S WATKINS; J D STUBBS; W LEWIN
Journal:  Lancet       Date:  1961-02-18       Impact factor: 79.321

5.  The clinical use of urea for reduction of intraocular pressure.

Authors:  M D DAVIS; P A DUEHR; M JAVID
Journal:  Arch Ophthalmol       Date:  1961-04

6.  Toxicity of urea and its role in the pathogenesis of uremia.

Authors:  E F GROLLMAN; A GROLLMAN
Journal:  J Clin Invest       Date:  1959-05       Impact factor: 14.808

7.  INTRAVENOUS UREA THERAPY IN GLAUCOMA.

Authors:  S J Crews; S I Davidson
Journal:  Br J Ophthalmol       Date:  1961-12       Impact factor: 4.638
  7 in total
  2 in total

Review 1.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial.

Authors:  Katherine Mb Ajdukiewicz; Katharine E Cartwright; Matthew Scarborough; James B Mwambene; Patrick Goodson; Malcolm E Molyneux; Eduard E Zijlstra; Neil French; Christopher Jm Whitty; David G Lalloo
Journal:  Lancet Infect Dis       Date:  2011-02-18       Impact factor: 25.071
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.